Home › Research › Risk genes beyond APOE
Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine
Wang R, Yan H, Tang XC.. Acta pharmacologica Sinica, 2006-01-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Huperzine A (HupA), a novel alkaloid isolated from the Chinese herb Huperzia serrata, is a potent, highly specific and reversible inhibitor of acetylcholinesterase(AChE). Compared with tacrine, donepezil, and rivastigmine, HupA has better penetration through the blood-brain barrier, higher oral bioavailability, and longer duration of AChE inhibitory action. HupA has been found to improve cognitive deficits in a broad range of animal models.
What this study adds
Evidence grade: Low
This is a narrative review. Huperzine A, a cholinesterase inhibitor from a Chinese herb, improved cognitive deficits in animal models and protected cells against several toxic insults. These are animal and cell findings, so its usefulness for treating Alzheimer's disease in people is not established here.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wang, R., Yan, H., & Tang, X. C. (2006). Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta pharmacologica Sinica. https://doi.org/10.1111/j.1745-7254.2006.00255.x
Vancouver
Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta pharmacologica Sinica. 2006. doi:10.1111/j.1745-7254.2006.00255.x. PMID: 16364207.
BibTeX
@article{wang2006-16364207,
author = {Wang, R. and Yan, H. and Tang, X. C.},
title = {{Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine}},
journal = {Acta pharmacologica Sinica},
year = {2006},
doi = {10.1111/j.1745-7254.2006.00255.x},
pmid = {16364207},
url = {https://doi.org/10.1111/j.1745-7254.2006.00255.x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Compared with tacrine, donepezil, and rivastigmine, HupA has better penetration through the blood-brain barrier, higher oral bioavailability, and longer duration of AChE inhibitory action.
- HupA has been found to improve cognitive deficits in a broad range of animal models.
- HupA possesses the ability to protect cells against hydrogen peroxide, beta-amyloid protein (or peptide), glutamate, ischemia and staurosporine-induced cytotoxicity and apoptosis.
- These protective effects are related to its ability to attenuate oxidative stress, regulate the expression of apoptotic proteins Bcl-2, Bax, P53, and caspase-3, protect mitochondria, upregulate nerve growth factor and its receptors, and interfere with amyloid precursor protein metabolism.
Why it matters
Huperzine A, a cholinesterase inhibitor from a Chinese herb, improved cognitive deficits in animal models and protected cells against several toxic insults. These are animal and cell findings, so its usefulness for treating Alzheimer's disease in people is not established here.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Acta pharmacologica Sinica) |
| Journal's citation record | 1 / 4 | Acta Pharmacologica Sinica: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2006 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 471 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 21.4 citations a year over 22 year(s) since 2006 |
| Impact for its field and year | 4 / 6 | Cited 13.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 45 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Xi-Can Tang: h-index 21 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Chinese Academy of Sciences: institution h-index 1,801 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16364207) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Risk genes beyond APOE from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.